POINT RICHMOND, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the appointment of Janet L. Nibel as Vice President of Finance and Administration. Ms. Nibel will have responsibility for all financial aspects of the company's operations and reporting as well as human resources, information technology and facilities. Ms. Nibel will report to Edward Lanphier, Sangamo's president and chief executive officer.
"Jan brings over 15 years of operational and finance experience that includes 10 years of experience in biotech," said Edward Lanphier. "As a member of the Incyte senior staff she saw the company through its growth from a 10-member start-up to a profitable corporation with international presence. Her broad array of skills, comprehensive knowledge of the biotechnology sector and experience in the industry will be a tremendous asset to Sangamo."
Ms. Nibel has been a member of senior management teams of biotechnology companies engaged in human clinical trials, small molecule drug development, genomic information as well as development of patent protected diagnostics. Most recently, Ms. Nibel was chief scientific officer of Layton BioScience, Inc., a private biopharmaceutical company that develops and markets therapies for the central nervous system. Prior to her position at Layton, she was chief scientific officer of diaDexus, a joint venture of Incyte Pharmaceuticals, Inc. and SmithKline Beecham, a company that she joined after spending 6 years with Incyte in various senior financial roles.
Ms. Nibel earned her undergraduate degree cum laude from the University of Central Oklahoma and is a member of the American Institute of Certified Public Accountants, the Association of BioScience Financial Officers and Financial Executives International... |
